Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06986993 · ClinicalTrials.gov registry record · Phase 4

Impact of Semaglutide on Tobacco Use and Related Health Behaviors

A Phase 4 study of Tobacco Use, sponsored by University of Oklahoma.

Recruiting
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT06986993 is a Phase 4 study of Tobacco Use that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 40 participants, below the 379-participant average among 76 other Tobacco Use trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06986993, a Phase 4 study of Tobacco Use, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via continuous glucose monitoring \[CGM\], etc.) in adult smokers with obesity (n = 40). We will integrate molecular biology procedures (e.g., epigenetics) to maximize internal validity with real-world smartphone-based ecological momentary assessment (EMA) surveys to maximize external validity

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Semaglutide

Study Locations (1)

Oklahoma

  • Health Promotion Research Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-07-01
Est. Completion 2028-06-30
Phase Phase 4

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT06986993

The ClinicalTrials.gov registry entry for NCT06986993 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 76 other Tobacco Use trials with a reported enrollment target (89% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06986993 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT06986993 about?

NCT06986993 is a clinical study titled "Impact of Semaglutide on Tobacco Use and Related Health Behaviors". This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via c...

What is the current status of trial NCT06986993?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2024-07-01. Estimated completion is 2028-06-30.

What conditions does trial NCT06986993 study?

This clinical trial studies the following conditions: Tobacco Use.

What interventions are being tested in trial NCT06986993?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).

Who is sponsoring clinical trial NCT06986993?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06986993 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.